

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

INSIDE INFORMATION
INVESTIGATION AGAINST AN INDEPENDENT NON-EXECUTIVE
DIRECTOR

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2), 13.51(2) and 13.51B(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has been notified that on 12 May 2026, Dr. Xiaoping Ye (“**Dr. Ye**”), an independent non-executive Director of the Company, received a case filing notice from the China Securities Regulatory Commission (the “**CSRC**”) in relation to suspected violations of laws and regulations regarding information disclosure related to changes in shareholding of Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ; 3347.HK), and the CSRC has decided to initiate an investigation into Dr. Ye in accordance with the Securities Law of the People’s Republic of China, the Administrative Penalty Law of the People’s Republic of China and other laws and regulations. Dr. Ye will actively cooperate with the CSRC’s relevant work and will fulfill his information disclosure obligations in strict accordance with regulatory requirements.

Dr. Ye is an independent non-executive Director of the Company and does not participate in the day-to-day management or operations of the Group. The board of directors of the Company believes that the business operation of the Group remains normal, and that the aforementioned investigation will not affect the Group’s normal operations. Further announcement(s) will be made to keep the shareholders of the Company and the public informed of the development in this matter in due course.

The shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 13 May 2026

As at the date of this announcement, the board of directors comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.